AKT1 and endometrial cancer: It has been demonstrated that only AKT1 and AKT2 isoforms are responsible for the acquisition of resistance against cisplatin and paclitaxel while all three isoforms of AKT increase doxorubicin resistance in endometrial cancer cells [98].